Clinical trial
Immunogenicity and Safety of Verorab™ in Indian Population
NCT00260351 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00260351 |
|---|---|
| Title | Immunogenicity and Safety of Verorab™ in Indian Population |
| Official title | Immunogenicity and Safety of Purified Vero Cell Rabies Vaccine (PVRV, Verorab™) Administered for Rabies Post-exposure Treatment. Comparison of Essen-IM, Zagreb-IM, and Thai Red Cross (TRC)-ID Regimens in the Indian Population. |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rabies |
| Intervention type | Biological |
| Interventions | Purified Verocell Rabies Vaccine |
| Enrollment | 405 |
| Start date | Dec 1, 2004 |
| Primary completion | Aug 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Dec 1, 2005 |
| Last update posted | Jan 14, 2014 |
| Countries | India |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: